Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer

   Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer

PR Newswire

JERSEY CITY, N.J., May 13, 2013

JERSEY CITY, N.J., May13, 2013 /PRNewswire/ --Optimer Pharmaceuticals
(NASDAQ: OPTR) (the "Company" or "Optimer") today announced the appointment of
Mr.Eric Sirota as Chief Operating Officer. Mr.Sirota will be responsible
for directing Optimer's corporate strategy with regard to DIFICID®.

"Eric has tremendous experience and has demonstrated leadership in building
pharmaceutical brands in the United States and abroad and has dedicated his
career to making important new medicines available to the medical profession
for the benefit of patients," said Dr. Hank McKinnell, Chairman and CEO of
Optimer. "His appointment fills a significant need at Optimer, and will allow
me to focus more of my time on the strategic review process we announced in
late February. Keeping the core business functioning well during this process
is critical to Optimer and its stockholders, and Eric will be responsible for
maintaining and growing our operations."

Mr. Sirota, 51 years old, operated a consultant practice in the healthcare
industry for more than three years, consulting with numerous pharmaceutical
companies and healthcare service organizations to develop new, and enhance
existing, business opportunities with a focus on strategy, operational
efficiency and organizational design. Mr. Sirota has served as a consultant
to the Company since March 8, 2013, providing product marketing and business
advice to Optimer's Board of Directors and Dr. McKinnell. In addition, from
February 2010 until December 2010, Mr.Sirota served as President of
Commercial Services of inVentiv Health, Inc., a provider of clinical,
commercial and consulting services to the healthcare industry, where he
developed strategies to address the need for integrated analytic, sales and
marketing solutions that enhance brand revenue, drive efficiency and lower
costs. Prior to June 2009, Mr. Sirota served as an executive of Pfizer Inc.,
most recently as Vice President of Pfizer's US Marketing, Commercial Strategy
and Innovation and Regional Sales, responsible for the neuroscience and pain
franchises. During his over twenty-year career at Pfizer, Mr. Sirota was
responsible for 12 therapeutic areas and more than 25 brands, including
anti-infectives. He received his B.S. degree in Pharmacy from Rutgers College
of Pharmacy and his Master of Business Administration degree from The Wharton
School, The University of Pennsylvania.

About Optimer Pharmaceuticals

We are a global biopharmaceutical company currently focused on commercializing
our antibiotic product DIFICID® (fidaxomicin) tablets in the United States and
Canada, and developing other fidaxomicin products in the United States and
worldwide, both by ourselves and with our partners and licensees. DIFICID, a
macrolide antibacterial drug, was approved by the U.S. Food and Drug
Administration on May 27, 2011, for the treatment of Clostridium
difficile-associated diarrhea, or CDAD, in adults 18 years of age and older.
Fidaxomicin has also received marketing authorization in other jurisdictions,
including the European Union, where it is marketed under the trade name
DIFICLIR™ by our licensee, Astellas Pharma Europe. CDAD is the most common
symptom of Clostridium difficile infection, or CDI. Additional information can
be found at http://www.optimerpharma.com.

Forward-looking Statements

Statements included in this press release that are not a description of
historical facts are forward-looking statements, including, without
limitation, statements related to future roles and contributions of Mr. Sirota
at Optimer. Words such as "believes," "anticipates," "plans," "expects,"
"intend," "will," "seek," "potential," "maximize," "goal" and similar
expressions are intended to identify forward-looking statements. The
inclusion of forward-looking statements should not be regarded as a
representation by Optimer that any of its plans will be achieved. These
forward-looking statements are based on management's expectations on the date
of this release. Actual results may differ materially from those set forth in
this release due to the risks and uncertainties inherent in Optimer's business
including, without limitation, risks relating to: Optimer's ability to
continue driving adoption and use of DIFICID, the effects of changes in
Optimer's management, the outcome of Optimer's review of strategic
alternatives including a possible sale of the Company, the potential for
lawsuits and enforcement proceedings related to the previously disclosed
investigations by U.S. authorities and other risks detailed in Optimer's
filings with the Securities and Exchange Commission. Forward-looking
statements speak only as of the date of this release, and Optimer undertakes
no obligation to update or revise these statements, except as may be required
by law.

Contacts
Optimer Pharmaceuticals,Inc.
David Walsey, Vice President,Investor Relations and Corporate Communications
(858) 964-3418

Canale Communications
Jason I. Spark, Senior Vice President
(619) 849-6005



SOURCE Optimer Pharmaceuticals

Website: http://www.optimerpharma.com
 
Press spacebar to pause and continue. Press esc to stop.